Setmelanotide clinical summary.pdf (720.36 kB)

Setmelanotide in obesity: a profile of its use

online resource

posted on 2022-07-15, 00:11 authored by Connie Kang

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest C. Kang is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.

Abstract

Setmelanotide (IMCIVREE^®), a melanocortin-4 receptor agonist, meets a previously unmet need and thus represents an important advancement in the management of patients with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency obesity. Setmelanotide is the first approved treatment in patients with these conditions. In two single-arm, open-label, multicentre, phase III trials, subcutaneous setmelanotide was effective in reducing body weight by at least 10% after approximately 1 year of treatment at individualised therapeutic doses in patients aged 6 years and above with POMC, PCSK1 or LEPR deficiency obesity. Other outcomes relating to weight loss and self-reported hunger scores were also improved with setmelanotide therapy. Setmelanotide was generally well tolerated in clinical trials.